BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 28489075)

  • 1. Lipoprotein-biomimetic nanostructure enables efficient targeting delivery of siRNA to Ras-activated glioblastoma cells via macropinocytosis.
    Huang JL; Jiang G; Song QX; Gu X; Hu M; Wang XL; Song HH; Chen LP; Lin YY; Jiang D; Chen J; Feng JF; Qiu YM; Jiang JY; Jiang XG; Chen HZ; Gao XL
    Nat Commun; 2017 May; 8():15144. PubMed ID: 28489075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model.
    Lee TJ; Haque F; Shu D; Yoo JY; Li H; Yokel RA; Horbinski C; Kim TH; Kim SH; Kwon CH; Nakano I; Kaur B; Guo P; Croce CM
    Oncotarget; 2015 Jun; 6(17):14766-76. PubMed ID: 25885522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A tumor-targeting cRGD-EGFR siRNA conjugate and its anti-tumor effect on glioblastoma in vitro and in vivo.
    He S; Cen B; Liao L; Wang Z; Qin Y; Wu Z; Liao W; Zhang Z; Ji A
    Drug Deliv; 2017 Nov; 24(1):471-481. PubMed ID: 28181832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts.
    Grzelinski M; Urban-Klein B; Martens T; Lamszus K; Bakowsky U; Höbel S; Czubayko F; Aigner A
    Hum Gene Ther; 2006 Jul; 17(7):751-66. PubMed ID: 16839274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclodextrin-Based Nanostructure Efficiently Delivers siRNA to Glioblastoma Cells Preferentially via Macropinocytosis.
    Manzanares D; Pérez-Carrión MD; Jiménez Blanco JL; Ortiz Mellet C; García Fernández JM; Ceña V
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration.
    Van Woensel M; Wauthoz N; Rosière R; Mathieu V; Kiss R; Lefranc F; Steelant B; Dilissen E; Van Gool SW; Mathivet T; Gerhardt H; Amighi K; De Vleeschouwer S
    J Control Release; 2016 Apr; 227():71-81. PubMed ID: 26902800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma.
    Michiue H; Eguchi A; Scadeng M; Dowdy SF
    Cancer Biol Ther; 2009 Dec; 8(23):2306-13. PubMed ID: 19901546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catabolic pathways regulated by mTORC1 are pivotal for survival and growth of cancer cells expressing mutant Ras.
    Sung S; Choi J; Cheong H
    Oncotarget; 2015 Dec; 6(38):40405-17. PubMed ID: 26575954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer.
    Du Y; Shang BY; Sheng WJ; Zhang SH; Li Y; Miao QF; Zhen YS
    Oncotarget; 2016 Sep; 7(36):58418-58434. PubMed ID: 27517152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Charge Conversional Biomimetic Nanocomplexes as a Multifunctional Platform for Boosting Orthotopic Glioblastoma RNAi Therapy.
    Liu Y; Zou Y; Feng C; Lee A; Yin J; Chung R; Park JB; Rizos H; Tao W; Zheng M; Farokhzad OC; Shi B
    Nano Lett; 2020 Mar; 20(3):1637-1646. PubMed ID: 32013452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient systemic delivery of siRNA by using high-density lipoprotein-mimicking peptide lipid nanoparticles.
    Lin Q; Chen J; Jin H; Ng KK; Yang M; Cao W; Ding L; Zhang Z; Zheng G
    Nanomedicine (Lond); 2012 Dec; 7(12):1813-25. PubMed ID: 22830501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Boosting RNAi therapy for orthotopic glioblastoma with nontoxic brain-targeting chimaeric polymersomes.
    Shi Y; Jiang Y; Cao J; Yang W; Zhang J; Meng F; Zhong Z
    J Control Release; 2018 Dec; 292():163-171. PubMed ID: 30408555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-oncogenic activities of cyclin D1b siRNA on human bladder cancer cells via induction of apoptosis and suppression of cancer cell stemness and invasiveness.
    Kim CJ; Terado T; Tambe Y; Mukaisho KI; Sugihara H; Kawauchi A; Inoue H
    Int J Oncol; 2018 Jan; 52(1):231-240. PubMed ID: 29115414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing VDAC1 expression induces a non-apoptotic role for pro-apoptotic proteins in cancer cell differentiation.
    Arif T; Krelin Y; Shoshan-Barmatz V
    Biochim Biophys Acta; 2016 Aug; 1857(8):1228-1242. PubMed ID: 27080741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic effect of STAT3‑targeted small interfering RNA and AZD0530 against glioblastoma in vitro and in vivo.
    Liu Q; Wang L; Li D; Zhao J; Chen S; Li J
    Mol Med Rep; 2019 Oct; 20(4):3625-3632. PubMed ID: 31485668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers.
    Karpel-Massler G; Horst BA; Shu C; Chau L; Tsujiuchi T; Bruce JN; Canoll P; Greene LA; Angelastro JM; Siegelin MD
    Clin Cancer Res; 2016 Sep; 22(18):4698-711. PubMed ID: 27126996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy.
    De Backer L; Cerrada A; Pérez-Gil J; De Smedt SC; Raemdonck K
    J Control Release; 2015 Dec; 220(Pt B):642-50. PubMed ID: 26363301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivering siRNA and Chemotherapeutic Molecules Across BBB and BTB for Intracranial Glioblastoma Therapy.
    Yang ZZ; Gao W; Liu YJ; Pang N; Qi XR
    Mol Pharm; 2017 Apr; 14(4):1012-1022. PubMed ID: 28252970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo.
    Lee SJ; Yook S; Yhee JY; Yoon HY; Kim MG; Ku SH; Kim SH; Park JH; Jeong JH; Kwon IC; Lee S; Lee H; Kim K
    J Control Release; 2015 Dec; 220(Pt B):631-41. PubMed ID: 26307351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERK mediated upregulation of death receptor 5 overcomes the lack of p53 functionality in the diaminothiazole DAT1 induced apoptosis in colon cancer models: efficiency of DAT1 in Ras-Raf mutated cells.
    Thamkachy R; Kumar R; Rajasekharan KN; Sengupta S
    Mol Cancer; 2016 Mar; 15():22. PubMed ID: 26956619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.